Seems like investors are no longer that confident about Esperion's approach to lowering LDL. In their last Phase 2 trial, they seemed to have achieved endpoints, but stock is getting hammered. It was well over $100/share a month ago, now struggling to stay over $60 with some analysts predicting $40.

Looks like they'll be trying to run a Phase 3 with about 4000 patients at same time as Resverlogix, but hopefully recruiting a different set of people.

I wonder if RVX is somehow (mistakenly) being viewed in a smilar fashion. With PCSK9 inhibitors being big pharmas favorite at this time, it might be that investors don't understand that we target increasing HDL and not lowering LDL. At least CETP inhibitors are no longer viewed as the solution.

Time will tell.

masila